vs

Side-by-side financial comparison of AVINO SILVER & GOLD MINES LTD (ASM) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

AVINO SILVER & GOLD MINES LTD is the larger business by last-quarter revenue ($21.0M vs $20.6M, roughly 1.0× Pulmonx Corp). AVINO SILVER & GOLD MINES LTD runs the higher net margin — 36.6% vs -66.3%, a 102.9% gap on every dollar of revenue. On growth, AVINO SILVER & GOLD MINES LTD posted the faster year-over-year revenue change (44.0% vs -8.7%). Over the past eight quarters, AVINO SILVER & GOLD MINES LTD's revenue compounded faster (51.1% CAGR vs -0.5%).

Avino Silver & Gold Mines Ltd is a Canada-based mining company engaged in the exploration, development, and production of precious and base metals, primarily silver, gold, and copper. It operates its flagship Avino Mine property in Durango, Mexico, with its metal products supplied to global industrial and commodity markets.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

ASM vs LUNG — Head-to-Head

Bigger by revenue
ASM
ASM
1.0× larger
ASM
$21.0M
$20.6M
LUNG
Growing faster (revenue YoY)
ASM
ASM
+52.6% gap
ASM
44.0%
-8.7%
LUNG
Higher net margin
ASM
ASM
102.9% more per $
ASM
36.6%
-66.3%
LUNG
Faster 2-yr revenue CAGR
ASM
ASM
Annualised
ASM
51.1%
-0.5%
LUNG

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
ASM
ASM
LUNG
LUNG
Revenue
$21.0M
$20.6M
Net Profit
$7.7M
$-13.7M
Gross Margin
47.1%
77.9%
Operating Margin
-40.9%
Net Margin
36.6%
-66.3%
Revenue YoY
44.0%
-8.7%
Net Profit YoY
558.9%
5.5%
EPS (diluted)
$0.05
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASM
ASM
LUNG
LUNG
Q1 26
$20.6M
Q4 25
$22.6M
Q3 25
$21.0M
$21.5M
Q2 25
$21.8M
$23.9M
Q1 25
$18.8M
$22.5M
Q4 24
$23.8M
Q3 24
$14.6M
$20.4M
Q2 24
$14.8M
$20.8M
Net Profit
ASM
ASM
LUNG
LUNG
Q1 26
$-13.7M
Q4 25
$-10.4M
Q3 25
$7.7M
$-14.0M
Q2 25
$2.9M
$-15.2M
Q1 25
$5.6M
$-14.4M
Q4 24
$-13.2M
Q3 24
$1.2M
$-14.1M
Q2 24
$1.2M
$-15.3M
Gross Margin
ASM
ASM
LUNG
LUNG
Q1 26
77.9%
Q4 25
77.6%
Q3 25
47.1%
74.7%
Q2 25
46.9%
72.1%
Q1 25
56.1%
72.5%
Q4 24
74.0%
Q3 24
39.1%
73.7%
Q2 24
31.8%
73.7%
Operating Margin
ASM
ASM
LUNG
LUNG
Q1 26
-40.9%
Q4 25
-43.8%
Q3 25
-66.9%
Q2 25
-62.0%
Q1 25
-64.6%
Q4 24
-56.5%
Q3 24
-69.3%
Q2 24
-75.2%
Net Margin
ASM
ASM
LUNG
LUNG
Q1 26
-66.3%
Q4 25
-46.1%
Q3 25
36.6%
-64.9%
Q2 25
13.1%
-63.6%
Q1 25
29.8%
-64.1%
Q4 24
-55.4%
Q3 24
8.0%
-69.4%
Q2 24
8.4%
-73.7%
EPS (diluted)
ASM
ASM
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$-0.25
Q3 25
$0.05
$-0.34
Q2 25
$0.02
$-0.38
Q1 25
$0.04
$-0.36
Q4 24
$-0.33
Q3 24
$0.01
$-0.36
Q2 24
$0.01
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASM
ASM
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$57.3M
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$182.1M
$45.8M
Total Assets
$221.9M
$120.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASM
ASM
LUNG
LUNG
Q1 26
$61.6M
Q4 25
$69.8M
Q3 25
$57.3M
$76.5M
Q2 25
$37.3M
$75.5M
Q1 25
$26.6M
$74.6M
Q4 24
$70.9M
Q3 24
$7.8M
$63.3M
Q2 24
$5.3M
$63.5M
Total Debt
ASM
ASM
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
ASM
ASM
LUNG
LUNG
Q1 26
$45.8M
Q4 25
$54.1M
Q3 25
$182.1M
$60.0M
Q2 25
$144.8M
$69.1M
Q1 25
$132.3M
$77.7M
Q4 24
$85.8M
Q3 24
$114.5M
$93.9M
Q2 24
$112.2M
$101.2M
Total Assets
ASM
ASM
LUNG
LUNG
Q1 26
$120.0M
Q4 25
$129.3M
Q3 25
$221.9M
$138.3M
Q2 25
$174.7M
$147.2M
Q1 25
$157.7M
$150.7M
Q4 24
$162.8M
Q3 24
$135.4M
$167.4M
Q2 24
$133.7M
$172.6M
Debt / Equity
ASM
ASM
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASM
ASM
LUNG
LUNG
Operating Cash FlowLast quarter
$8.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.08×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASM
ASM
LUNG
LUNG
Q1 26
Q4 25
$-7.1M
Q3 25
$8.3M
$-8.2M
Q2 25
$8.3M
$-3.9M
Q1 25
$758.0K
$-13.2M
Q4 24
$-6.7M
Q3 24
$4.1M
$-7.2M
Q2 24
$1.1M
$-5.8M
Free Cash Flow
ASM
ASM
LUNG
LUNG
Q1 26
Q4 25
$-7.1M
Q3 25
$-8.3M
Q2 25
$-4.0M
Q1 25
$-13.5M
Q4 24
$-6.8M
Q3 24
$-7.7M
Q2 24
$-6.2M
FCF Margin
ASM
ASM
LUNG
LUNG
Q1 26
Q4 25
-31.4%
Q3 25
-38.4%
Q2 25
-16.6%
Q1 25
-60.0%
Q4 24
-28.8%
Q3 24
-37.6%
Q2 24
-30.0%
Capex Intensity
ASM
ASM
LUNG
LUNG
Q1 26
Q4 25
0.1%
Q3 25
0.4%
Q2 25
0.2%
Q1 25
1.3%
Q4 24
0.5%
Q3 24
2.0%
Q2 24
2.3%
Cash Conversion
ASM
ASM
LUNG
LUNG
Q1 26
Q4 25
Q3 25
1.08×
Q2 25
2.92×
Q1 25
0.13×
Q4 24
Q3 24
3.55×
Q2 24
0.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons